1992年至1997年加拿大蒙特利尔脆弱拟杆菌群临床分离株的抗菌药物耐药性趋势
Trends in antimicrobial resistance among clinical isolates of the Bacteroides fragilis group from 1992 to 1997 in Montreal, Canada.
作者信息
Labbé A C, Bourgault A M, Vincelette J, Turgeon P L, Lamothe F
机构信息
Département de Microbiologie Médicale et Infectiologie, Centre Hospitalier de l'Université de Montréal, Montréal, Canada.
出版信息
Antimicrob Agents Chemother. 1999 Oct;43(10):2517-9. doi: 10.1128/AAC.43.10.2517.
Abstract
The objective of the present study was to analyze the susceptibility profiles of 911 clinical strains of the Bacteroides fragilis group isolated from 1992 to 1997 in our institution in order to monitor susceptibility changes over time. Whereas the rates of resistance to metronidazole, imipenem, piperacillin-tazobactam, ticarcillin-clavulanic acid, penicillin, piperacillin, and cefoxitin remained essentially unchanged, there was a significant increase in the rates of resistance to clindamycin, which rose from 8.2% in 1992 to 19.7% in 1997 (P < 0.0004).
摘要
本研究的目的是分析1992年至1997年期间从我们机构分离出的911株脆弱拟杆菌属临床菌株的药敏谱，以监测随时间的药敏变化。虽然对甲硝唑、亚胺培南、哌拉西林-他唑巴坦、替卡西林-克拉维酸、青霉素、哌拉西林和头孢西丁的耐药率基本保持不变，但对克林霉素的耐药率显著增加，从1992年的8.2%升至1997年的19.7%（P<0.0004）。
相似文献
1
Trends in antimicrobial resistance among clinical isolates of the Bacteroides fragilis group from 1992 to 1997 in Montreal, Canada.
Antimicrob Agents Chemother. 1999 Oct;43(10):2517-9. doi: 10.1128/AAC.43.10.2517.
2
Survey of Bacteroides fragilis group susceptibility patterns in Canada.
Antimicrob Agents Chemother. 1992 Feb;36(2):343-7. doi: 10.1128/AAC.36.2.343.
3
Cross-resistance to beta-lactam-beta-lactamase inhibitor combinations and clindamycin among cefoxitin-resistant and cefoxitin-susceptible strains of the Bacteroides fragilis group.
Diagn Microbiol Infect Dis. 1993 Oct;17(3):251-6. doi: 10.1016/0732-8893(93)90107-i.
4
Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole.
J Antimicrob Chemother. 1993 Mar;31(3):363-72. doi: 10.1093/jac/31.3.363.
5
Susceptibility trends of Bacteroides fragilis group isolates from Buenos Aires, Argentina.
Rev Argent Microbiol. 2007 Jul-Sep;39(3):156-60.
6
Analysis of trends in antimicrobial resistance patterns among clinical isolates of Bacteroides fragilis group species from 1990 to 1994.
Clin Infect Dis. 1996 Dec;23 Suppl 1:S54-65. doi: 10.1093/clinids/23.supplement_1.s54.
7
In vitro activities of clindamycin, imipenem, metronidazole, and piperacillin-tazobactam against susceptible and resistant isolates of Bacteroides fragilis evaluated by kill kinetics.
Antimicrob Agents Chemother. 2012 Jun;56(6):3413-6. doi: 10.1128/AAC.00099-12. Epub 2012 Mar 19.
8
Resistance trends of Bacteroides fragilis group over an 8-year period, 1997-2004, in Korea.
Korean J Lab Med. 2009 Aug;29(4):293-8. doi: 10.3343/kjlm.2009.29.4.293.
9
Susceptibility trends of Bacteroides fragilis group and characterisation of carbapenemase-producing strains by automated REP-PCR and MALDI TOF.
Anaerobe. 2012 Feb;18(1):37-43. doi: 10.1016/j.anaerobe.2011.12.022. Epub 2012 Jan 11.
10
Susceptibility of 114 isolates of the Bacteroides fragilis group to imipenem and eight other antimicrobial agents.
Pathology. 1988 Jul;20(3):260-3. doi: 10.3109/00313028809059504.
引用本文的文献
1
Antibiotic optimization in the difficult-to-treat patient with complicated intra-abdominal or complicated skin and skin structure infections: focus on tigecycline.
Ther Clin Risk Manag. 2010 Sep 7;6:419-30. doi: 10.2147/tcrm.s9117.
2
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
Antimicrob Agents Chemother. 2008 Sep;52(9):3161-8. doi: 10.1128/AAC.00355-08. Epub 2008 Jul 14.
3
Bacteroides fragilis group: trends in resistance.
Curr Microbiol. 2006 Feb;52(2):153-7. doi: 10.1007/s00284-005-0249-x. Epub 2006 Jan 31.
4
Activities of garenoxacin (BMS-284756) and other agents against anaerobic clinical isolates.
Antimicrob Agents Chemother. 2003 Mar;47(3):910-6. doi: 10.1128/AAC.47.3.910-916.2003.
5
High incidence of cefoxitin and clindamycin resistance among anaerobes in Taiwan.
Antimicrob Agents Chemother. 2002 Sep;46(9):2908-13. doi: 10.1128/AAC.46.9.2908-2913.2002.
6
In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain.
Antimicrob Agents Chemother. 2002 Mar;46(3):892-5. doi: 10.1128/AAC.46.3.892-895.2002.
7
In vitro activities of MK-0826 and 16 other antimicrobials against Bacteroides fragilis group strains.
Antimicrob Agents Chemother. 2001 Aug;45(8):2372-4. doi: 10.1128/AAC.45.8.2372-2374.2001.
8
Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species.
Antimicrob Agents Chemother. 2001 Apr;45(4):1238-43. doi: 10.1128/AAC.45.4.1238-1243.2001.
本文引用的文献
1
Trends in antimicrobial resistance of the Bacteroides fragilis group: a 20-year study at a medical center in Buenos Aires, Argentina.
Clin Infect Dis. 1997 Sep;25 Suppl 2:S268-9. doi: 10.1086/516192.
2
Clindamycin resistance in the Bacteroides fragilis group: association with hospital-acquired infections.
Clin Infect Dis. 1997 May;24(5):874-7. doi: 10.1093/clinids/24.5.874.
3
Antimicrobial resistance in anaerobes.
Clin Infect Dis. 1997 Jan;24 Suppl 1:S110-20. doi: 10.1093/clinids/24.supplement_1.s110.
4
Emerging resistance of anaerobic bacteria to antimicrobial agents in South Korea.
Clin Infect Dis. 1996 Dec;23 Suppl 1:S73-7. doi: 10.1093/clinids/23.supplement_1.s73.
5
Analysis of trends in antimicrobial resistance patterns among clinical isolates of Bacteroides fragilis group species from 1990 to 1994.
Clin Infect Dis. 1996 Dec;23 Suppl 1:S54-65. doi: 10.1093/clinids/23.supplement_1.s54.
6
Present studies of therapy for anaerobic infections.
Clin Infect Dis. 1996 Dec;23 Suppl 1:S9-14. doi: 10.1093/clinids/23.supplement_1.s9.
7
Longitudinal study of susceptibilities of species of the Bacteroides fragilis group to five antimicrobial agents in three medical centers.
Antimicrob Agents Chemother. 1994 Oct;38(10):2276-9. doi: 10.1128/AAC.38.10.2276.
8
Survey of anaerobic susceptibility patterns in Canada.
Antimicrob Agents Chemother. 1986 Nov;30(5):798-801. doi: 10.1128/AAC.30.5.798.
9
Evolution of antimicrobial susceptibility in isolates of the Bacteroides fragilis group in Spain.
Rev Infect Dis. 1990 Jan-Feb;12 Suppl 2:S142-51. doi: 10.1093/clinids/12.supplement_2.s142.
10
Survey of Bacteroides fragilis group susceptibility patterns in Canada.
Antimicrob Agents Chemother. 1992 Feb;36(2):343-7. doi: 10.1128/AAC.36.2.343.
Zotero 插件